Vertex Pharmaceuticals (WBO:VRTX) Float Percentage Of Total Shares Outstanding: 88.56% (As of Jul. 01, 2026)


WBO:VRTX Vertex Pharmaceuticals Inc WBO:VRTX
91 GF Score
Price €438.30
GF Value €440.30
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Vertex Pharmaceuticals WBO:VRTX +0.67% 91 Float Percentage Of Total Shares Outstanding is 88.56% as of Jul. 01, 2026. GuruFocus rates WBO:VRTX with a GF Score™ of 91/100 and a GF Value™ of €440.30 (Fairly Valued). The stock has 4 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Vertex Pharmaceuticals's float shares is 224.77 Mil. Vertex Pharmaceuticals's total shares outstanding is 253.81 Mil. Vertex Pharmaceuticals's float percentage of total shares outstanding is 88.56%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Vertex Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Vertex Pharmaceuticals's Institutional Ownership is 90.23%.

WBO:VRTX
91GF Score
Vertex Pharmaceuticals Inc WBO:VRTX
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vertex Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Vertex Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=224.77/253.81
=88.56%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 88.56% mean?
Vertex Pharmaceuticals (WBO:VRTX) has a Float Percentage Of Total Shares Outstanding of 88.56% as of Jul. 01, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Vertex Pharmaceuticals and its competitors.
Is Vertex Pharmaceuticals' Float Percentage Of Total Shares Outstanding too high?
Vertex Pharmaceuticals' current Float Percentage Of Total Shares Outstanding is 88.56%. Overall, Vertex Pharmaceuticals has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Float Percentage Of Total Shares Outstanding compare to REGN and ALNY?
Vertex Pharmaceuticals' Float Percentage Of Total Shares Outstanding of 88.56% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Float Percentage Of Total Shares Outstanding is 88.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (WBO:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is €440.30, compared to a current price of €438.30 — trading 0.5% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 88.56%. Vertex Pharmaceuticals' overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Vertex Pharmaceuticals (WBO:VRTX), the current Float Percentage Of Total Shares Outstanding is 88.56% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (WBO:VRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of €438.30 is trading 0.5% below its estimated GF Value™ of €440.30. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for WBO:VRTX:

  • Float Percentage Of Total Shares Outstanding: 88.56%
  • GF Value™: €440.30 vs. price of €438.30 (0.5% below fair value)
  • GF Score™: 91/100 with 4 warning signs

No single metric tells the full story. See the WBO:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
91GF Score

Get the complete analysis for WBO:VRTX

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€438.30
Price
€440.30
GF Value